Sangamo Therapeutics, Inc. (SGMOQ)
0.1423
-0.02
(-11.17%)
USD |
OTCM |
Aug 21, 16:00
Sangamo Therapeutics Shareholders Equity (Quarterly) : -18.96M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -18.96M |
| December 31, 2025 | -14.27M |
| September 30, 2025 | 6.243M |
| June 30, 2025 | 19.60M |
| March 31, 2025 | 4.906M |
| December 31, 2024 | 22.77M |
| September 30, 2024 | 39.13M |
| June 30, 2024 | 23.69M |
| March 31, 2024 | 56.70M |
| December 31, 2023 | 82.89M |
| September 30, 2023 | 134.92M |
| June 30, 2023 | 233.64M |
| March 31, 2023 | 335.61M |
| December 31, 2022 | 294.96M |
| September 30, 2022 | 309.15M |
| June 30, 2022 | 318.28M |
| March 31, 2022 | 334.52M |
| December 31, 2021 | 375.34M |
| September 30, 2021 | 406.02M |
| June 30, 2021 | 445.46M |
| March 31, 2021 | 470.36M |
| December 31, 2020 | 498.23M |
| September 30, 2020 | 521.41M |
| June 30, 2020 | 511.46M |
| March 31, 2020 | 394.29M |
| Date | Value |
|---|---|
| December 31, 2019 | 432.55M |
| September 30, 2019 | 419.09M |
| June 30, 2019 | 445.13M |
| March 31, 2019 | 328.50M |
| December 31, 2018 | 366.52M |
| September 30, 2018 | 379.91M |
| June 30, 2018 | 387.87M |
| March 31, 2018 | 182.36M |
| December 31, 2017 | 187.90M |
| September 30, 2017 | 186.65M |
| June 30, 2017 | 194.04M |
| March 31, 2017 | 125.68M |
| December 31, 2016 | 136.20M |
| September 30, 2016 | 143.84M |
| June 30, 2016 | 160.02M |
| March 31, 2016 | 179.41M |
| December 31, 2015 | 192.44M |
| September 30, 2015 | 203.56M |
| June 30, 2015 | 199.94M |
| March 31, 2015 | 207.49M |
| December 31, 2014 | 206.63M |
| September 30, 2014 | 210.14M |
| June 30, 2014 | 214.36M |
| March 31, 2014 | 217.42M |
| December 31, 2013 | 121.71M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
| Vicapsys Life Sciences, Inc. | -3.549M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 59.96M |
| Total Liabilities (Quarterly) | 78.92M |
| Debt to Equity Ratio | -1.020 |
| Current Ratio | 0.6985 |
| Net Debt Paydown Yield | 2.20% |